Evidence map›Paper›PMID 40722658›Full record

ArticleBiomedicines2025

Implication of p16 Promoter Methylation, the BRAFV600E Mutation, and ETS1 Expression Determination on Papillary Thyroid Carcinoma Prognosis and High-Risk Patients' Selection.

Stefana Stojanović Novković, Sonja Šelemetjev, Milena Krajnović, Ana Božović, Bojana Kožik, Uršula Prosenc Zmrzljak, Tijana Išić Denčić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Stefana Stojanović NovkovićDepartment of Endocrinology and Radioimmunology, Institute for the Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, Zemun, 11080 Belgrade, Serbia.
Sonja ŠelemetjevDepartment of Endocrinology and Radioimmunology, Institute for the Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, Zemun, 11080 Belgrade, Serbia.ORCID 0000-0002-2898-6671
Milena KrajnovićLaboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovića Alasa 12-14, Vinča, 11351 Belgrade, Serbia.
Ana BožovićLaboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovića Alasa 12-14, Vinča, 11351 Belgrade, Serbia.
Bojana KožikLaboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovića Alasa 12-14, Vinča, 11351 Belgrade, Serbia.ORCID 0000-0002-2983-4151
Uršula Prosenc ZmrzljakMolecular Biology Laboratory, BIA Separations CRO-Labena d.o.o, 1000 Ljubljana, Slovenia.ORCID 0000-0002-9034-790X
Tijana Išić DenčićDepartment of Endocrinology and Radioimmunology, Institute for the Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, Zemun, 11080 Belgrade, Serbia.ORCID 0000-0001-8475-2266

Funding

This research was funded by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia Agreement No. 451-03-136/2025-03/200019
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

epigeneticpatients’ stratificationpredictionPTCtumor aggressivenesstumor marker

Identifiers

PMID40722658
PMCPMC12292734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.